ArticleOncoimmunology2020

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.

Cyrill A Rentsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.